NEW YORK: Vaccine creator Novavax Inc said on Monday it has pushed back the beginning of a U.S.- based, late-stage preliminary for its test COVID-19 immunization and now anticipates that it should start in the coming a long time rather than November.
It is the second time that Novavax, which as of now has a late-stage UK preliminary in progress, has rescheduled the Phase 3 preliminary after first hailing an October start, hampered by issues in scaling up its assembling.
Portions of the U.S.- based organization, which lingers behind bigger adversaries Pfizer Inc and Moderna Inc in their COVID-19 antibody improvement timetables, fell 6% on the most recent deferral.
Novavax plans to utilize immunization material delivered at business scale for the preliminary in the United States and Mexico and has been working intimately with the U.S. Food and Drug Administration to greenlight the utilization of the immunization made at a North Carolina plant.
